Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
PerkinElmer Inc. (PKI) drives innovation in diagnostics, life sciences, and applied markets through advanced scientific solutions. This page aggregates official announcements and verified news about the company's strategic initiatives, financial performance, and technological advancements.
Investors and industry professionals will find timely updates on earnings reports, product launches, and regulatory milestones. Our curated collection simplifies tracking PKI's progress in enabling critical research and improving healthcare outcomes globally.
Key content includes updates on analytical instrumentation developments, partnership announcements with research institutions, and expansions in diagnostic testing capabilities. All materials adhere to strict factual reporting standards without speculative commentary.
Bookmark this page for streamlined access to PerkinElmer's latest corporate communications. Check back regularly for insights into how PKI continues to address complex challenges in scientific discovery and clinical diagnostics.
PerkinElmer has launched two innovative no-wash assay kits, HTRF® and AlphaLISA®, aimed at detecting and quantifying CHO HCP impurities in biopharmaceutical manufacturing. These kits enhance efficiency by streamlining workflows and improving sensitivity compared to traditional methods. The assays are designed for high-throughput capabilities with the ability to process samples in 384-well plates, addressing challenges in biomanufacturing. This development supports PerkinElmer's comprehensive solutions for drug development from discovery to quality control.
PerkinElmer, a leader in health innovation, will present at the Cowen 42nd Annual Health Care Conference and the Barclays Global Healthcare Conference. The Cowen conference is scheduled for March 7, 2022, with Jamey Mock, CFO, presenting at 10:30 a.m. ET. Following this, Prahlad Singh, CEO, will present at the Barclays conference on March 15, 2022, at 1:30 p.m. ET in Miami. Both presentations will provide insights on the company's strategic priorities, with live audio webcasts available on their website, where replays will also be accessible for 90 days post-event.
PerkinElmer, a leader in health innovation, will present at Citi’s Virtual Healthcare Conference on February 24, 2022, at 8:45 a.m. ET. CEO Prahlad Singh will discuss the company's strategic priorities. Interested participants can register here. A live webcast will also be available on the Investors section of the company’s website, with a replay accessible for 90 days post-event.
PerkinElmer reported $5.0 billion in revenue for 2021 and operates in 190 countries.
EUROIMMUN, a subsidiary of PerkinElmer (NYSE:PKI), announced the inclusion of its Anti-Dengue Virus NS1 Type 1-4 ELISA (IgG) test in the CDC's pre-vaccination screening for the Dengvaxia vaccine. This test is crucial for ensuring that children aged 9-16, who have a laboratory-confirmed previous dengue infection, can access the vaccine in dengue-endemic areas. In 2019, dengue cases reached record levels, emphasizing the need for effective diagnostic solutions. The assay focuses on virus-specific antibodies, enabling better vaccination strategies against dengue disease.
PerkinElmer reported 4Q 2021 revenue of $1.36 billion, reflecting a 1% reported growth but a -9% organic growth. GAAP EPS from continuing operations was $1.41, down from $3.38 in 4Q 2020. For the full year, GAAP revenue reached $5.067 billion, up from $3.783 billion in 2020, boasting a 32% increase. The company also announced its 2022 guidance, projecting first-quarter revenue between $1.17-$1.19 billion and full-year revenue of $4.42-$4.50 billion.
The Board of Directors of PerkinElmer (NYSE: PKI) announced a quarterly dividend of
PerkinElmer, Inc. (NYSE: PKI) anticipates exceeding its fourth quarter 2021 revenue and earnings guidance. Expected adjusted earnings per share is at least
PerkinElmer (NYSE: PKI) is set to present virtually at the J.P. Morgan Healthcare Conference on January 11, 2022, at 11:15 a.m. ET. The company's CEO, Prahlad Singh, will discuss strategic priorities and provide an update on operations. A live audio webcast will be accessible via the provided link, and a replay will be available on the PerkinElmer Investor Relations website for 30 days post-event. In 2020, PerkinElmer reported revenues of approximately $3.8 billion and employs over 16,000 staff globally, serving customers in 190 countries.
PerkinElmer, a leader in health innovations, has launched the NEXTFLEX® Variant-Seq™ SARS-CoV-2 Kit v2 for accelerated detection of SARS-CoV-2 variants, including Omicron. The kit enhances sequencing throughput and reduces turnaround time by three hours for 96 samples through advanced normalization beads. It incorporates 1,536 Unique Dual Index barcodes, allowing for the sequencing of 6,000 libraries in a single flow cell, lowering costs. This initiative aims to support SARS-CoV-2 surveillance efforts amid the ongoing pandemic.
PerkinElmer, Inc. (NYSE: PKI) announced that its SARS-CoV-2 RT-PCR assays remain effective despite the emergence of the Omicron variant of concern.
With over 30 reported mutations in the S gene, the company's assays do not target this gene and are unaffected by these changes. In silico assessments indicate no impact on diagnostic accuracy from the Omicron variant.
The company emphasizes the importance of reliable diagnostics amid ongoing concerns regarding transmissibility and vaccine resistance. PerkinElmer's solutions include a comprehensive SARS-CoV-2 portfolio.
FAQ
What is the market cap of PERKINELMER (PKI)?
